Targeted Oncology3h
High-Grade Toxicity Rates Influence Choice of IO in Melanoma
During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...
Head and Neck Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...
Advanced Cervical Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.
Medscape10h
Final Phase 2 Results Confirm Response Rates With Pembro + CRT for NSCLC
Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...
Le Lézard12h
NCCN Foundation Celebrates 2025 Young Investigator Award Recipients Shaping the Future of Cancer Research
The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® proudly announce four recipients for the 2025 NCCN Foundation Young Investigator Awards (YIA). These awards provide ...